Equity Overview
Price & Market Data
Price: $15.96
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $2,730,260,992
Daily Volume: 0
Performance Metrics
1 Week: -3.97%
1 Month: -5.51%
3 Months: 15.32%
6 Months: -23.67%
1 Year: -42.73%
YTD: -35.57%
Company Details
Employees: 362
Sector: Health technology
Industry: Biotechnology
Country:
Details
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.